LivaNova Price Target Raised to $85 Following Record Q2 Revenue

Key Facts

In a move reflecting the robust performance of the medical technology sector, Stifel Nicolaus has raised its price target for LivaNova to $85.00. This adjustment follows the company's record second-quarter revenue of $390.60 million, representing a 9.80% increase on a constant-currency basis. Furthermore, adjusted diluted earnings per share reached $1.26, surpassing consensus estimates by a significant 16.67%.

According to analyst reports, this growth was primarily driven by double-digit expansion in the Cardiopulmonary and Epilepsy segments, leading the company to raise its full-year guidance for both revenue and adjusted EPS. However, the forecast for adjusted free cash flow was lowered to accommodate increased capital expenditures in manufacturing and IT infrastructure. At the time the target was set, the new valuation implied a potential upside of approximately 10.99%.

While current market price levels for LIVN are unavailable at this time (close 2026-08-05), the outlook remains bullish due to the upward revision of annual guidance. Investors should monitor broader market sentiment as recent data shows varying business confidence levels across global markets, which may influence the healthcare sector's momentum in the coming sessions.